Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study: The data collection on adverse events of anti-HIV drugs (D:A:D) study group

AIDS

Volumn 24, Issue 10, 2010, Pages 1537-1548

  Smith, Colette ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

death; modifiable risk factors

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; DIABETES MELLITUS; FEMALE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NEOPLASM; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SMOKING;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; AUSTRALIA; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; EUROPE; FEMALE; HIV INFECTIONS; HUMANS; MALE; NEOPLASMS; RISK FACTORS; UNITED STATES;

EID: 77953913058     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833a0918     Document Type: Article

References (37)

1. Mocroft A, Ledergerber B, Katlama C, Kirk KA, Reiss P, d'Armi-nio Monforte A, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22-29.
2. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-860.
3. 3 compared with the general population. 15th Conference on Retroviruses and Opportunistic Infections, February 3-6 2008, Boston, USA. 2008. Ref Type: Abstract.
4. Bhaskaran K, Hamouda O, Sannes M, Boufassa F, Johnson AM, Lambert PC, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008; 300:51-59.
5. Marin B, Thiebaut R, Bucher HC, Rondeau V, Costagliola D, Dorrucci M, et al. Non-AIDS defining deaths and immunodeficiency in the era of combination antiretroviral therapy. CASCADE, 1996-2006. AIDS 2009; 23:1743-1753.
6. Lewden C, May T, Rosenthal E, Burty C, Bonnet F, Costagliola D, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalité 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008; 48:590-598.
7. Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2008; 166:1632-1641.
8. Sabin CA, Worm SW. Conventional cardiovascular risk factors in HIV infection: how conventional are they? Curr Opin HIV AIDS 2008; 3:214-219.
9. Urbanus AT, van de Laar TJ, Stolte IG, Schinkel J, Heijman T, Coutinho RA, et al. Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic. AIDS 2009; 23:F1-F7.
10. The Data Collection oAdverse Events of Anti-HIV Drugs (D:A:D) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
11. Olsen CH, Friis-Moller N, d'Arminio Monforte A, Chene G, Davey R, De Wit S, et al. Pilot of the CoDe (Coding of Death) project: a standardized approach to code causes of death in HIV infected individuals. 10th European AIDS Conference, 17-20 November 2005, Dublin, Ireland. 2005.
12. Jaggy C, von Overbeck J, Ledergerber B, Schwarz C, Egger M, Rickenbach M, et al. Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population. Lancet 2003; 362:877-878. (Pubitemid 37130098)
13. Bonnet F, Burty C, Lewden C, Costagliola D, May T, Bouteloup V, et al. Changes in cancer mortality among HIV-infected patients: the Mortalité 2005 Survey. Clin Infect Dis 2009; 48:633-639.
14. Choi AI, Rodriguez RA, Bacchetti P, Bertenthal D, Volberding PA, O'Hare AM. The impact of HIV on chronic kidney disease outcomes. Kidney Int 2007; 72:1380-1387. (Pubitemid 350126779)
15. Gerard Y, Viget N, Yazdanpanah Y, Ajana F, de La Tribonniere X, Bocket L, et al. Hyperlactataemia during antiretroviral therapy: incidences, clinical data and treatment. Therapie 2003; 58:153-158.
16. Smith CJ, Mocroft A, Olsen CH, Antunes F, Staszewski S, Domingo P, et al. Incidence of pancreatitis amongst HIV-positive individuals, and the association with triglycerides and antiretroviral use. 11th European AIDS Conference, October 24-27, Madrid, Spain 2007; Abstract number P9.10/02.
17. Cook RL, Zhu F, Belnap BH, Weber K, Cook JA, Vlahov D, et al. Am J Epidemiol 2009; 169:1025-1032.
18. Preau M, Bouhnik AD, Peretti-Watel P, Obadia Y, Spire B, ANRS-EN12-VESSPA Group. Suicide attempts among people living with HIV in France. AIDS Care 2008; 20:917-924.
19. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund B, et al. Inferior clinical outcome of the CD4R cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4R cell counts and HIV RNA levels during follow-up. J Infect Dis 2008; 197:1145-1155.
20. Phillips AN, Neaton J, Lundgren JD. The role of HIV in serious diseases other than AIDS. AIDS 2008; 22:2409-2418.
21. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, et al. CD4R count-guided interruption of anti-retroviral treatment. N Engl J Med 2006; 355:2283-2296.
22. http://insight.ccbr.umn.edu/start/. START Trial Website [Accessed 13 July 2009]
23. Neaton JD, Grund B. Earlier initiation of antiretroviral therapy in treatment-näive patients: implications of results of treatment interruption trials. Curr Opin HIV AIDS 2008; 3:112-117.
24. 3: primary results of the ESPRIT Study. 16th Conference on Retroviruses and Opportunistic Infections, 8-11 February 2009, Montreal, Canada 2009; 90aLB
25. US Department of Health and Human Services. The health benefits of smoking cessation: a report of the Surgeon General. Washington DC: US Department of Health and Human Services, Public Health Service 1990; Centers for Disease Control and Prevention, Center for Chronic Disease Prevention and Health Promotion, Officeon Smoking and Health, 1990; DHHS Publication No. (CDC) 90-8416.
26. Duval X, Baron G, Garelik D, Villes V, Dupre T, Leport C, et al. Living with HIV, antiretroviral treatment experience and tobacco smoking: results from a multisite cross-sectional study. Antivir Ther 2008; 13:389-397.
27. R smokers. 16th Conference on Retro-viruses and Opportunistic Infections, 8-11 February 2009, Montreal, Canada Oral 148. 2009. Ref Type: Abstract.
28. McClure JB, Ludman EJ, Grothaus L, Pabiniak C, Richards J. Impact of a brief motivational smoking cessation intervention the get PHIT randomized controlled trial. Am J Prev Med 2009; 37:116-123.
29. Uto H, Stuver SO, Hayashi K, Kumagai K, Sasaki F, Kanmura S, et al. Increased rate of death related to presence of viremia among hepatitis C virus antibody-positive subjects in a community-based cohort study. Hepatology 2009; 50:393-399.
30. Hoffmann CJ, Seaberg EC, Young S, Witt MD, D'acunto K, Phair J, et al. Hepatitis B and long-term HIV outcomes in coinfected HAART recipients. AIDS 2009; 23:1881-1889.
31. Hansen AB, Gerstoft J, Kronborg G, Pedersen C, Sorensen HT, Obel N. Mortality in siblings of patients coinfected with HIV and hepatitis C virus. J Infect Dis 2007; 195:230-235.
32. Terrault NA. Benefits and risks of combination therapy for hepatitis B. Hepatology 2009; 49 (5 Suppl):S122-S128.
33. Chen CJ, Yang HI, Iloeje UH, REVEAL-HBV Study Group. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology 2009; 49 (5 Suppl):S72-S84.
34. Berenguer J, Alvarez-Pellicer J, Martin PM, Lopez-Aldeguer J, Von-Wichmann MA, Quereda C, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009; 50:407-413.
35. Zinkernagel AS, von Wyl V, Ledergerber B, Rickenbach M, Furrer H, Battegay M, et al. Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study. Antivir Ther 2006; 11:131-142.
36. Gerver S, Chadborn T, Ibrahim F, Riberio S, Vatsa B, Delpeche V, et al. Retention in Care/ART and Loss to Follow-Up. XVII International AIDS Conference, 3-8 August 2008, Mexico City, Mexico 2008; TUAB0205.
37. Friis-Moller N, Reiss P, El-Sadr W, d'Arminio Monforte A, Thiebaut R, De Wit S, et al. Exposure to PI and NNRTI and risk of myocardial infaction: results from the D:A:D Study. 13th Conference on Retroviruses and Opportunistic Infections, Denver, February 2006 2006.